NO20054673L - Anvendelse av pyridin-2yl-metylaminderivater for fremstilling av et medikament beregnet for behandling av nevropatiske og psykogene kroniske smertesymptomer - Google Patents

Anvendelse av pyridin-2yl-metylaminderivater for fremstilling av et medikament beregnet for behandling av nevropatiske og psykogene kroniske smertesymptomer

Info

Publication number
NO20054673L
NO20054673L NO20054673A NO20054673A NO20054673L NO 20054673 L NO20054673 L NO 20054673L NO 20054673 A NO20054673 A NO 20054673A NO 20054673 A NO20054673 A NO 20054673A NO 20054673 L NO20054673 L NO 20054673L
Authority
NO
Norway
Prior art keywords
neuropathic
treatment
chronic pain
analgesic
alkyl
Prior art date
Application number
NO20054673A
Other languages
English (en)
Other versions
NO334997B1 (no
Inventor
Francis Colpaert
Bernard Vacher
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of NO20054673L publication Critical patent/NO20054673L/no
Publication of NO334997B1 publication Critical patent/NO334997B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Oppfinnelsen angår anvendelsen av en forbindelse med formel (I) og terapeutisk akseptable saler derav, nærmere bestemt hvor u = metyl, v og W = H, x = F, y = Cl, x = F, A = H eller aminometyl, og farmasøytisk akseptable addisjonssalter med mineral- eller organiske syrer for fremstilling av et medikament for behandlingen av kroniske smertesymptomer av nevropatisk eller psykogent opphav.
NO20054673A 2003-03-13 2005-10-11 Anvendelse av pyridin-2yl-metylaminderivater for fremstilling av et medikament beregnet for behandling av nevropatiske og psykogene kroniske smertesymptomer NO334997B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0303099A FR2852244B1 (fr) 2003-03-13 2003-03-13 Utilisation de derives de pyridin-2-yl-methylamine pour la preparation d'un medicament destine au traitement des symptomes de la douleur chronique d'origine neuropathique ou psychogene
PCT/FR2004/000630 WO2004083171A2 (fr) 2003-03-13 2004-03-15 Utilisation de derives de pyridin-2-yl-methylamine pour le traitement des symptomes de la douleur chronique neuropathique ou psychogene

Publications (2)

Publication Number Publication Date
NO20054673L true NO20054673L (no) 2005-10-11
NO334997B1 NO334997B1 (no) 2014-08-18

Family

ID=32893267

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054673A NO334997B1 (no) 2003-03-13 2005-10-11 Anvendelse av pyridin-2yl-metylaminderivater for fremstilling av et medikament beregnet for behandling av nevropatiske og psykogene kroniske smertesymptomer

Country Status (25)

Country Link
US (1) US8609694B2 (no)
EP (1) EP1603564B1 (no)
JP (1) JP4684994B2 (no)
KR (1) KR101100002B1 (no)
CN (1) CN1761467B (no)
AT (1) ATE366111T1 (no)
AU (1) AU2004222051B2 (no)
BR (1) BRPI0408293A (no)
CA (1) CA2518591C (no)
CY (1) CY1106900T1 (no)
DE (1) DE602004007364T2 (no)
DK (1) DK1603564T3 (no)
ES (1) ES2289494T3 (no)
FR (1) FR2852244B1 (no)
HK (1) HK1079120A1 (no)
IL (1) IL170743A (no)
MX (1) MXPA05009782A (no)
NO (1) NO334997B1 (no)
NZ (1) NZ542461A (no)
PL (1) PL1603564T3 (no)
PT (1) PT1603564E (no)
RU (1) RU2359674C2 (no)
UA (1) UA81023C2 (no)
WO (1) WO2004083171A2 (no)
ZA (1) ZA200507634B (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071778B2 (en) 2006-07-27 2011-12-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009096941A1 (en) * 2008-01-28 2009-08-06 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in cns disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020346A (en) 1995-01-12 2000-02-01 Glaxo Wellcome Inc. Piperidine derivatives having tachykinin antagonist activity
FR2755967B1 (fr) * 1996-11-21 1999-01-29 Pf Medicament Derives de la pyridin-2-yl-methylamine, leur procede de preparation et leur application comme medicaments
FR2784378B1 (fr) * 1998-10-09 2000-12-29 Pf Medicament Nouveaux derives d'aryl-(4-fluoro-4-[(2-pyridin-2-yl- ethylamino)-methyl]-piperidin-1-yl)-methanone, leur procede de preparation et leur utilisation a titre de medicaments
FR2840900B1 (fr) * 2002-06-18 2005-02-25 Pf Medicament Nouveaux derives d'aryl[4-halogeno-4- [(heteroaryl-methylamino)-methyl]-piperidin-1-yl]-methanone, leur procede de preparation et leur utilisation a titre de medicaments

Also Published As

Publication number Publication date
WO2004083171A3 (fr) 2004-12-23
AU2004222051A1 (en) 2004-09-30
DE602004007364D1 (de) 2007-08-16
CA2518591A1 (fr) 2004-09-30
CN1761467B (zh) 2011-09-21
DK1603564T3 (da) 2007-10-01
PL1603564T3 (pl) 2007-12-31
JP2006520370A (ja) 2006-09-07
ZA200507634B (en) 2006-06-28
AU2004222051B2 (en) 2009-01-15
RU2359674C2 (ru) 2009-06-27
JP4684994B2 (ja) 2011-05-18
FR2852244A1 (fr) 2004-09-17
NZ542461A (en) 2008-10-31
CN1761467A (zh) 2006-04-19
EP1603564A2 (fr) 2005-12-14
IL170743A (en) 2011-11-30
IL170743A0 (en) 2009-02-11
CA2518591C (fr) 2012-05-15
MXPA05009782A (es) 2005-12-05
CY1106900T1 (el) 2012-09-26
DE602004007364T2 (de) 2008-03-06
RU2005131615A (ru) 2006-02-10
ATE366111T1 (de) 2007-07-15
BRPI0408293A (pt) 2006-03-07
KR101100002B1 (ko) 2011-12-28
FR2852244B1 (fr) 2007-09-07
US20060241141A1 (en) 2006-10-26
WO2004083171A2 (fr) 2004-09-30
NO334997B1 (no) 2014-08-18
ES2289494T3 (es) 2008-02-01
KR20050106120A (ko) 2005-11-08
PT1603564E (pt) 2007-09-24
UA81023C2 (en) 2007-11-26
US8609694B2 (en) 2013-12-17
EP1603564B1 (fr) 2007-07-04
HK1079120A1 (en) 2006-03-31

Similar Documents

Publication Publication Date Title
US20210023043A1 (en) Methods of Treating Hyperalgesia
KR101855357B1 (ko) 오피오이드 유도성 통각과민에서의 시그마 리간드의 용도
US9789117B2 (en) Use of sigma ligands in diabetes type-2 associated pain
US11260059B2 (en) Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
TWI629984B (zh) σ配體在與間質性膀胱炎／膀胱疼痛綜合徵（ＩＣ／ＢＰＳ）相關的疼痛的預防和治療中的應用
KR20110021823A (ko) 진통 내성 억제제
WO2006049312A1 (ja) 神経因性疼痛治療剤
CN111065390A (zh) Kor激动剂与mor激动剂联合在制备治疗疼痛的药物中的用途
JP4706636B2 (ja) 鎮痛剤
Lundin et al. Analgesic effects of intra-articular morphine during and after knee arthroscopy: a comparison of two methods
NO20054673L (no) Anvendelse av pyridin-2yl-metylaminderivater for fremstilling av et medikament beregnet for behandling av nevropatiske og psykogene kroniske smertesymptomer
JP3559572B2 (ja) 急性痛および慢性痛用鎮痛剤
JPH05132430A (ja) 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法
Raghuraman Intrathecal nalbuphine–Will it gain wider acceptance?–A narrative review
US20070259945A1 (en) Method for treating pain
Lauretti Highlights in opioid agonists and antagonists
MX2022004610A (es) Uso de derivado de fenilquinolinona o derivado flavonoide para tratamiento del dolor neuropático.
Kamali et al. Analgesic efficacy of bupivacaine alone versus bupivacaine plus dexmedetomidine in penile block for hypospadias surgery
Dmytro et al. Selecting the ideal adjuvant to improve neuraxial and regional analgesia: A narrative review
Xuelun et al. Analgesic effect of morphine added to bupivacaine in transversus abdominis plane block for total abdominal hysterectomy
US20210228555A1 (en) Method of treatment with tradipitant
WO2006060190A2 (en) Imidazole derivatives
WO2020106454A3 (en) Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
Kim The Effect of Intraarticular Morphine and Clonidine on Postoperative Analgesia after Knee Surgery.
Ashton et al. Neuropharmacological profile of R 18 503-induced wet-shake behavior in the rat: Noradrenergic and opiate components

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees